Video
Dr. Blakely on the Design of a Trial Evaluating Osimertinib in Resectable EGFR-Mutant NSCLC
Author(s):
Collin Blakely MD, PhD, discusses the design of an ongoing phase 2 trial examining osimertinib in resectable EGFR-mutant non–small cell lung cancer.
Collin Blakely MD, PhD, associate professor of medicine, University of California, San Francisco (UCSF), medical oncologist, UCSF Health, discusses the design of an ongoing phase 2 trial (NCT03433469) examining osimertinib (Tagrisso) in resectable EGFR-mutant non–small cell lung cancer (NSCLC).
The non-randomized, multi-institution trial screened patients with stage I to IIIA NSCLC, Blakely explains. Patients who have EGFR activating mutations, such as an L858R mutation or an exon 19 deletion, were eligible for enrollment, Blakely adds. Patients who met all screening criteria received 1 to 2 months of neoadjuvant osimertinib, followed by standard surgical resection, Blakely says.
The tissue was analyzed for major pathological response and patients were continuously followed after surgery to examine disease-free and overall survival, Blakely continued. In the adjuvant setting, patients could receive physician’s choice of standard therapy, such as chemotherapy or osimertinib, Blakely concludes.
